CA Patent

CA2389896A1 — Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation

Assigned to Medac Gesellschaft fuer Klinische Spezialpraeparate mbH · Expires 2001-05-10 · 25y expired

What this patent protects

The invention relates to the use of treosulfan as a conditioning agent before allogenic transplantation of bone marrow or haematopoietic stem cells, whereby treosulfan is administered, either as single effective agent, or in combination with other chemotherapetic agents or immuno…

USPTO Abstract

The invention relates to the use of treosulfan as a conditioning agent before allogenic transplantation of bone marrow or haematopoietic stem cells, whereby treosulfan is administered, either as single effective agent, or in combination with other chemotherapetic agents or immunosuppressant agents.

Drugs covered by this patent

Patent Metadata

Patent number
CA2389896A1
Jurisdiction
CA
Classification
—
Expires
2001-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.